Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma-Reference-Cited by-同舟云学术

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma

Published:2021-06-18 Issue:12 Volume:35 Page:3581-3584
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Graham Charlotte Elizabeth^ORCID,Jozwik Agnieszka,Quartey-Papafio Ruby,Ioannou Nikolaos,Metelo Ana M.,Scala Carlo,Dickson Glenda,Stewart Orla,Almena-Carrasco Maria,Peranzoni Elisa,Ramsay Alan G.,Patten Piers E. M.^ORCID,Pertel Thomas,Farzaneh Farzin,Dupouy Sandra,Pepper Andrea^ORCID,Benjamin Reuben

Funder

Servier

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01324-z.pdf

Reference15 articles.

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531–44.

2. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

3. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.